NCT03572491View on ClinicalTrials.gov

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

May 21, 2018

Study Completion Date

May 21, 2018

Conditions
Human Influenza
Interventions
BIOLOGICAL

influenza vaccine

Allantoic split inactivated seasonal influenza vaccine

Trial Locations (1)

080409

Research Institute for Biological Safety Problems, Gvardeysky

All Listed Sponsors
collaborator

Asfendiyarov Kazakh National Medical University

OTHER

collaborator

Research Institute of Influenza, Russia

OTHER

lead

Research Institute for Biological Safety Problems

OTHER_GOV

NCT03572491 - Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine | Biotech Hunter | Biotech Hunter